Coronavirus disease 2019 in children: Clinical & epidemiological implications

Vijesh Sreedhar Kuttiall, Philip Raj Abraham, Ramesh P. Menon, Pankaj C. Vaidya & Manju Rahi

ICMR-Vector Control Research Centre, Puducherry, Cardiothoracic Centre, All India Institute of Medical Sciences, Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi & Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Received June 6, 2020

Despite the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are limited data emerging in children. This review provides an update on clinical features, diagnosis, epidemiology, management and prevention of coronavirus disease 2019 (COVID-19) in children. Specific characteristics noted in children and their implications in disease management as well as transmission control are highlighted. Besides respiratory symptoms, gastrointestinal and atypical features such as chilblains, neurological symptoms and multisystem inflammation are also reported. Younger infants and those with comorbidity were found to be at risk of severe illness. Infected pregnant women and neonates were reported to have good prognosis. It is possible to manage the children with mild disease at home, with strict infection prevention control measures; severely affected require respiratory support and intensive care management. There are anecdotal reports of using antiviral and immunomodulatory drugs, benefit of which needs to be confirmed in clinical trials. A significant percentage of asymptomatic infection in children has epidemiological implication as these may act as links in transmission chain in the community. There is a need for systematic data on extra-pulmonary manifestations and atypical features, risk factors of severity, role of imaging and biomarkers, testing and management strategies and trials with antivirals and immunomodulatory drugs in children. The psychosocial effects of quarantine, closure of schools, lack of play activities and impact of lockdown need to be addressed. Understanding the biological basis for the profound age-dependent differential outcome of COVID-19 infection is important. Elucidating the protective mechanisms in children may aid in developing novel treatment strategies.

Key words Children - clinical features - COVID-2019 - epidemiology - prevention - SARS-CoV-2 - severity of illness - treatment

Introduction

Coronavirus disease 2019 (COVID-19), since its origin in Wuhan city of Hubei Province in China in December 2019, became pandemic in less than 100 days. Globally, 11.5 million confirmed cases have been reported with mortality of 0.53 million by July 7, 2020. In India, the first case was detected on January 30, 2020 who was a student returned from Wuhan, China,
The incubation period is estimated to be 1-14 days, to acquire infection by close contact with infected adults. Transmission is not yet documented in neonates from infected mothers, but needs further confirmation. Vertical transmission is also speculated as virus shedding has been reported in faecal samples, especially in children, but needs further confirmation. Gastrointestinal (GI) route of transmission happened in many areas. A salient facet of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is that children and adolescents are found to be less affected. However, children as a vulnerable group pose unique challenges during the unprecedented pandemic. This review describes transmission characteristics, clinical manifestations, diagnostic, treatment and preventive aspects of COVID-19 in children. It also emphasizes on the need for conducting studies to understand the protective mechanisms in children as this has significant implications for the development of future therapeutics.

**SARS-CoV-2 and its origin**

The causative agent of the COVID-19 pandemic is SARS-CoV-2, which belongs to the Betacoronaviruses of the family Coronaviridae. Some coronaviruses, such as HCoV-229E, -HKU1, -NL63 and -OC43, are known to circulate among humans causing mild respiratory illness. However, coronaviruses are known to undergo rapid mutation and recombination forming novel viruses that may jump from animals to humans, resulting in severe disease. In December, 2019, a cluster of adults with pneumonia of unexplained aetiology was announced by the Health Commission of Hubei province, China. Further investigation confirmed the causative agent to be a novel coronavirus (n-CoV-2019), with 85 per cent genomic identity with a bat SARS-like coronavirus (MG772933.1, bat-SL-CoVZC45).

**Transmission characteristics and pathogenesis of SARS-CoV-2**

SARS-CoV-2 infection is transmitted predominantly through the respiratory route by droplets and by surface contact with fomites. Transmission of infection to healthcare staff may happen during aerosol-generating events such as intubation, ventilation, suction and nebulization in critical care units. Gastrointestinal (GI) route of transmission is also speculated as virus shedding has been reported in faecal samples, especially in children, but needs further confirmation. Transmission to neonates from infected mothers is known, but vertical transmission is not yet documented. Most children acquire infection by close contact with infected adults. The incubation period is estimated to be 1-14 days, with a median of 5-6 days. Virus can be detected in the upper respiratory tract 1-2 days before onset of symptoms and persists in the respiratory system for 7-12 days in moderate cases and up to two weeks in severe cases. Prolonged shedding of the virus has been observed in a few children with mild infections, up to 22 days in the respiratory tract and between two and four weeks in the faecal samples.

Our understanding of the pathogenesis and pathophysiology of COVID-19 is in the initial stages, and the studies are in progress. Angiotensin-converting enzyme 2 (ACE2) is identified as the main cellular entry receptor where the spike protein of the SARS-CoV-2 attaches and transmembrane protease serine 2 (TMPRSS2) acts as the co-receptor. In patients with severe diseases, elevated plasma levels of pro-inflammatory cytokines such as interleukin (IL)-6, IL-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1α, tumour necrosis factor-α and granulocyte-colony stimulating factor are observed, and a cytokine storm is also proposed in severely affected patients. A hypercoagulable profile with elevated D-dimer and fibrinogen level is noted, and probable endothelial cell injury is also postulated. Notable pathological findings are consolidation in the lungs with serous fluid, fibrin exudate and formation of hyaline membrane. In addition, alveolar septum hyperaemia, oedema, mononuclear and lymphocyte infiltration and intravascular thrombosis are also observed. Although most of the findings are from adults, limited data in a small number of children show increased levels of procalcitonin, C-reactive protein and D-dimer in those with moderate-to-severe disease.

**COVID-19 in children**

The global data showed that the proportion of children among the total number of COVID-19-affected patients was small and most children developed mild illness. One study from China has reported that children aged below 10 yr have the same susceptibility as adults to get infected, but unlikely to develop severe disease. Another study from China supports the concept that children are less susceptible to COVID-19 compared to adults. In this study, when the contact of people with known infections were traced and tested for the virus, for each affected child under the age of 15 yr, nearly three people were found to be infected between the ages of 20 and 64. The age group-wise distribution of cases and the differences...
in fatality rate in the published large case series from different countries are summarized in Table I. A recent study from India reported the clinical features and epidemiological characteristics of 21 patients in New Delhi. All had mild illness except one who had lung consolidation and required oxygen inhalation\(^{27}\). In this study, only one case was below 20 yr of age.

**Clinical manifestations**

Reports of paediatric infection are available from some affected global regions\(^{28-35}\), and two systematic reviews have been published based on the early data\(^{36,37}\). Among the affected children, a spectrum of manifestations was seen with varying grades of severity (asymptomatic/mild/moderate/severe/critical illness) and a few deaths were also noted\(^{25,28}\). Majority of the children develop only a mild illness, and present predominantly with fever and dry cough. Upper respiratory symptoms such as cold, nasal congestion and sore throat are less frequent. Severe cases manifest as dyspnoea and may rapidly worsen and develop acute respiratory distress syndrome (ARDS), shock, multi-organ failure and coagulopathy\(^{28}\). GI symptoms such as nausea, vomiting and loose stools are also reported in some affected children\(^{11,12}\).

In the largest published paediatric case series from China, young infants and those suffering from comorbid conditions were found to be vulnerable to the infection and affected severely\(^{28}\). Among the age groups of <1, 1-5, 6-10, 11-15 and \(\leq16\) yr, proportion of severe and critical cases were 10.6, 7.3, 4.2, 4.1 and 3.0 per cent, respectively. One child succumbed to the illness. A study on children hospitalized with COVID-19 in the paediatric intensive care units (ICUs) in the USA also reported pre-hospitalization comorbidities as an important factor in childhood COVID-19\(^{31}\). Chinese Experts’ Consensus Statement categorizes high-risk group as (i) those children in contact with severe COVID-19 case, (ii) those with underlying congenital heart disease, pulmonary disease, chronic cardiac/renal disease, malnutrition, diabetes, immunodeficiency and hereditary metabolic diseases, (iii) those receiving long-term immunosuppressants, and (iv) infants under three months\(^{38}\). Clinical characteristics of COVID-19 in children reported in various published studies are summarized in Table II.

Other clinical characteristics reported are the dermatological lesions, atypical presentation with neurological symptoms and the curious multi-system inflammatory syndrome, the Kawasaki disease. Chilblain-like skin lesions of the extremities termed ‘COVID toes’ have been observed in children in Italy and Spain\(^{39,40}\) but need further confirmation. Presentation with neurological symptoms such as axial hypotonia, drowsiness and moaning sounds or both, without respiratory manifestations, has also been reported in a few infants. Their cerebrospinal fluid parameters were normal, and all had a favourable outcome\(^{41}\). Multi-system inflammatory syndrome in children, mimicking the Kawasaki disease has been reported from COVID-19-affected regions in Europe as well as the USA, which needs to be characterized\(^{42,43}\). A link to COVID-19 is suspected but needs further research as reverse transcription-polymerase chain reaction (RT-PCR) test has been found to be negative in most of the cases\(^{43}\).

**COVID-19 case definitions**

The WHO has published case definitions of COVID-19, and individual countries have been encouraged to develop their own definitions suitable to the country situation, stage of the epidemic and resources available\(^{44}\). There are no separate criteria for children as of now but may be adapted from that of adults and modified as data emerge and as we come to know more about the disease in children. The Ministry of Health and Family Welfare (MoHFW), Government of India, has published guidelines for testing and treatment, being updated regularly as the scenario evolves and new scientific data emerge\(^{45}\). As per this, “COVID-19 should be suspected in a patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), and a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset; a patient with any acute respiratory illness and having been in contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset; or in a patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; and requiring hospitalization) and in the absence of an alternative diagnosis that fully explains the clinical presentation”. A probable case is a suspect case for whom testing for the COVID-19 virus is inconclusive, or testing could not be performed for any reason\(^{45}\).

Case definition criteria may require modification when community spread occurs, atypical or novel clinical presentations are noted, and when validated,
| Study | Country       | Total number of cases | Age group (yr) | Number of cases (%) | Deaths (%) | Case-fatality rate (%) |
|-------|---------------|-----------------------|----------------|---------------------|------------|------------------------|
|       |               |                       |                |                     |            |                        |
| The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team⁴ | China | 72,314 (confirmed cases - 44,672) | 0-9 | 416 (0.9) | - | - |
|       |               |                       | 10-19 | 549 (1.2) | 1 (0.1) | 0.2 |
|       |               |                       | 20-29 | 3619 (8.1) | 7 (0.7) | 0.2 |
|       |               |                       | 30-39 | 7600 (17.0) | 18 (1.8) | 0.2 |
|       |               |                       | 40-49 | 8571 (19.2) | 38 (3.7) | 0.4 |
|       |               |                       | 50-59 | 10,008 (22.4) | 130 (12.7) | 1.3 |
|       |               |                       | 60-69 | 8583 (19.2) | 312 (30.5) | 3.6 |
|       |               |                       | 70-79 | 3918 (8.8) | 309 (30.2) | 8.0 |
|       |               |                       | ≥80   | 1408 (3.2) | 208 (20.3) | 14.8 |
|       |               | Total                 |        | 44,672 | 1023 | 2.3 |
| Livingston and Bucher, 2020⁴ | Italy | 22,512 | 0-9 | Number of cases not available in the range taken for comparison (age group mentioned as 0-18, 19-50, 51-70 and >70 yr) | 0 | 0 |
|       |               |                       | 10-19 | 0 | 0 |
|       |               |                       | 20-29 | 0 | 0 |
|       |               |                       | 30-39 | 4 (0.2) | 4.3 | 0.3 |
|       |               |                       | 40-49 | 10 (0.6) | 10 (0.6) | 0.4 |
|       |               |                       | 50-59 | 43 (2.6) | 43 (2.6) | 1.0 |
|       |               |                       | 60-69 | 139 (8.5) | 139 (8.5) | 3.5 |
|       |               |                       | 70-79 | 578 (35.6) | 578 (35.6) | 12.5 |
|       |               |                       | 80-89 | 694 (42.7) | 694 (42.7) | 19.7 |
|       |               |                       | ≥90   | 156 (9.6) | 156 (9.6) | 22.7 |
|       |               | Not reported           |        | 1 (0.06) | 1 (0.06) | 0.6 |
|       |               | Total                 |        | 22,512 | 1625 (100) | 7.2 |
| CDC COVID-19 Response Team, USA⁵ | USA  | 4,226 (confirmed cases - 2,449) | 0-19 | 123 (5) | 0 | 0 |
|       |               |                       | 20-44 | 705 (29) | 9 (20) | 0.1-0.2  |
|       |               |                       | 45-54 | 429 (18) | 429 (18) | 0.5-0.8  |
|       |               |                       | 55-64 | 429 (18) | 429 (18) | 1.4-2.6  |
|       |               |                       | 65-74 | 409 (17) | 20 (46) | 2.7-4.9  |
|       |               |                       | 75-84 | 210 (9) | 210 (9) | 4.3-10.5 |
|       |               |                       | ≥85   | 144 (6) | 15 (34) | 10.4-27.3 |
|       |               | Total                 |        | 2449 | 44 | 1.8-3.4 |
| Korean Society of Infectious Diseases⁶ | South Korea | 4,212 | 0-9 | 32 (1) | 0 | 0 |
|       |               |                       | 10-19 | 169 (4) | 0 | 0 |
|       |               |                       | 20-29 | 1235 (30) | 0 | 0 |
|       |               |                       | 30-39 | 506 (12) | 1 (4.5) | 0.2 |
|       |               |                       | 40-49 | 633 (15) | 1 (4.5) | 0.2 |
|       |               |                       | 50-59 | 834 (20) | 5 (22.7) | 0.6 |
|       |               |                       | 60-69 | 530 (12) | 6 (27.3) | 1.1 |
|       |               |                       | 70-79 | 192 (5) | 6 (27.3) | 3.1 |
|       |               |                       | ≥80   | 81 (2) | 3 (13.6) | 3.7 |
|       |               | Total                 |        | 4,212 | 22 | 0.5 |

*In lower and upper bound ranges
### Table II. Clinical profile of coronavirus disease 2019 in children

| Study            | Country and period of the study          | Number of cases | Clinical manifestations, n (%)                      | Severity, n (%) and other characteristics                                      | Treatment, n (%) |
|------------------|------------------------------------------|-----------------|---------------------------------------------------|---------------------------------------------------------------------------------|-----------------|
| Dong et al²⁸     | China (January 16 to February 8, 2020)   | Total cases - 2,135 | Not mentioned                                    | Mild 314 (43.1) Moderate 298 (40.9) Severe 18 (2.5) Critical 3 (0.4) Missing 1 (0.2) Death 1 (0.1) (Only confirmed cases included) Asymptomatic 94 (12.9) | Not mentioned   |
|                  | Nation-wide case series                  | Confirmed cases - 728 |                                             |                                                                                 |                 |
|                  | Suspected cases - 1,407                  |                 |                                                  |                                                                                 |                 |
| CDC COVID-19 Response Team USA²⁹ | USA (February 12 to April 2, 2020)       | Total cases - 2,572 | Fever, cough, or shortness of breath 213 (73)  | Among 345 paediatric cases with information on underlying conditions, 80 (23) had at least one underlying condition. The most common underlying conditions were chronic lung disease (including asthma) (40), cardiovascular disease (25) and immunosuppression (10). Three deaths were reported | Not mentioned   |
|                  | Nation-wide case series                  | Data available for 291 cases only | Fever 163 (56) Cough 158 (54) Shortness of breath 39 (13) Myalgia 66 (23) Runny nose 21 (7.2) Sore throat 71 (24) Headache 81 (28) Nausea/vomiting 31 (11) Abdominal pain 17 (5.8) Diarrhoea 37 (13) |                                                                                 |                 |
| Lu et al³⁰       | China (January 28 to February 26, 2020)   | 1,391 children with known contact with confirmed or suspected SARS-CoV-2 infection were evaluated and 171 were confirmed cases | Cough 83 (48.5) Pharyngeal erythema 79 (46.2) Fever 71 (41.5) Median duration of fever (range) days 3 (1-16) Diarrhoea 15 (8.8) Fatigue 13 (7.6) Rhinorrhoea 13 (7.6) Vomiting 11 (6.4) Nasal congestion 9 (5.3) Tachypnoea on admission 49 (28.7) Tachycardia on admission 72 (42.1) Oxygen saturation <92% during period of hospitalization 4 (2.3) | Upper respiratory tract infection 33 (19.3) Pneumonia 111 (64.9) Asymptomatic infection 27 (15.8) A 10-month old child with intussusception had multi-organ failure and died four weeks after admission | Three patients required intensive care support and invasive mechanical ventilation; all had coexisting conditions [hydronephrosis, leukaemia (for which the patient was receiving maintenance chemotherapy), and intussusception] |
|                  | Wuhan Children’s Hospital, Hubei         |                 |                                                  |                                                                                 |                 |

Contd...
| Study                | Country and period of the study | Number of cases | Clinical manifestations, n (%) | Severity, n (%) and other characteristics | Treatment, n (%)                                                                 |
|---------------------|---------------------------------|-----------------|-------------------------------|------------------------------------------|--------------------------------------------------------------------------------|
| Shekerdemian et al | USA (March 14 to April 10, 2020) | 48 children admitted in paediatric intensive care unit (cross-sectional study) | Pre-existing comorbidities 40 (83)  
Respiratory symptoms 35 (73) | All were severe cases  
Two patients (4) died | 18 (38) required invasive ventilation  
Extracorporeal membrane oxygenation was required for 1 patient (2)  
28 patients (61) received targeted specific therapies  
The most common was hydroxychloroquine (alone or in combination)  
Azithromycin given in 8 children (alone in 1 case with hydroxychloroquine in 7 cases)  
Remdisivir used in 8 patients (alone in 2 and in combination in 6)  
Tocilizumab was used in 5 children (alone in 1 in combination with hydroxychloroquine in 1), in combination with hydroxychloroquine and azithromycin in 1, in combination with hydroxychloroquine and remdisivir in 1, and in combination with convalescent plasma in 1 patient |
| Tagarro et al       | Spain (March 2-16, 2020) by 30 secondary and tertiary hospitals in Madrid, Spain | 365 children were screened within the 30 hospitals, 41 confirmed cases | Respiratory tract infection 14 (34)  
Fever without a source 11 (27)  
Viral-like pneumonia 6 (15)  
Bronchiolitis 5 (12)  
Gastroenteritis or vomiting 2 (5)  
Bacterial-like pneumonia 2 (5)  
Asthma flare 1 (2)  
Co-infection with influenza B 2 (5) | Not mentioned 11 (27) had underlying comorbid conditions | Ventilation 4 (10) |
| Qiu et al           | China (January 17 to March 1, 2020) Zhejiang | 36 (retrospective case series) | Dry cough 7 (19)  
Dyspnoea or tachypnoea 1 (3)  
Pharyngeal congestion 1 (3)  
Sore throat 2 (6)  
Vomiting or diarrhoea 2 (6)  
Body temperature>37°C 13 (36)  
Headache 3 (8) | Mild 17 (47.2)  
Moderate 19 (52.8)  
Asymptomatic 10 (28) | Oxygen inhalation 6 (17)  
Interferon alpha 36 (100)  
Lopinavir-ritonavir 14 (39) |

Contd...
| Study          | Country and period of the study | Number of cases | Clinical manifestations, n (%) | Severity, n (%) and other characteristics | Treatment, n (%) |
|---------------|---------------------------------|----------------|---------------------------------|---------------------------------------------|-----------------|
| Wang et al13   | China (January 25 to February 21, 2020) 6 provinces (Shaanxi, Gansu, Ningxia, Hebei, Henan, and Shandong) of northern China | 31 (retrospective case series) | Fever 20 (65) Cough 14 (45) Fatigue 3 (10) Diarrhoea 3 (10) Sore throat, runny nose, dizziness, headache, vomiting were rare | Mild 13 (42) Moderate 14 (45) Asymptomatic 4 (13) | 29 cases (94), received antiviral treatment 10 cases, interferon alone 6 cases, antibacterial drugs 2 cases, intravenous gamma globulin 8 cases, traditional Chinese medicine |
| Zheng et al14   | China (February 1-10, 2020) A cross-sectional multicentre study Carried out in 10 hospitals across Hubei province | 25 (retrospective case series) | Fever 13 (52) Nasal congestion 2 (8) Cough 11 (44) Dyspnoea 2 (8) Abdominal pain 2 (8) Vomiting 2 (8) Diarrhoea 3 (12) | Upper respiratory infection 8 (32) Mild pneumonia 15 (60) Critical cases 2 (8) Co-infections: | Two cases received invasive mechanical ventilation and treated with immunoglobulin (2 g/kg), corticosteroid (2 mg/kg), antivirals (interferon, oseltamivir) and antibiotics (cefoperazone, sulbactam, meropenem, linezolid). One underwent continuous veno-venous haemodiafiltration and plasma exchange |
| Cai et al12    | China (January 19 to February 3, 2020) Children’s Hospital in Shanghai, Hainan, Hefei in Anhui province, and Qingdao in Shandong province | 10 (prospective case series) | Fever 8 (80) Cough 6 (60) Sore throat 4 (40), Stuffy nose 3 (30) Sneezing and rhinorrhoea 2 (20) None of patients had diarrhoea or dyspnoea during the course of illness | High frequency (83.3%) of SARS-CoV-2 RNA detected in faeces in patients with mild disease and also prolonged virus RNA shedding in faeces for at least two weeks and even more than a month | All patients received symptomatic treatment and five patients with pneumonia received empirical antibiotic therapy |
| Sun et al15    | China (January 24 to February 24, 2020) Wuhan Children’s Hospital, Hubei | 8 (severe or critically ill patients admitted in intensive care unit) | Polypnoea 8 (100) Fever 6 (75) Cough 6 (75) Expectoration 4 (50) Nausea 4 (50) Diarrhoea 3 (37.5) Fatigue/myalgia 1 (12.5) Headache 1 (12.5) Constipation 1 (12.5) | All severely/critically ill | Symptomatic and respiratory support, invasive mechanical ventilation (2 children) antiviral treatments (ribavirin, oseltamivir and interferon), antibiotic therapy, traditional Chinese medicine, intravenous glucocorticoid and immunoglobulin therapies were also used according to the patients’ conditions |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
rapid test or serological diagnostic assays or imaging tools are used. In this regard, mild nature of the illness, extra-pulmonary manifestations and atypical features in children need attention. Diagnosis of infection in children was based on the clinical manifestations and history of exposure\(^{28}\). If a child was exposed to a COVID-19 patient or lived in an epidemic area or community where COVID-19 cases were reported within the past two weeks, the child was defined as having high, medium or low-risk, respectively, based on the possibility of getting infected. A suspected case is defined when a child at high-risk has two of the following conditions: (i) fever or respiratory symptoms or GI symptoms such as vomiting, nausea and diarrhoea or fatigue, (ii) normal or decreased white blood cell count or elevated level of C-reactive protein, or (iii) abnormal chest X-ray findings. For children at medium or low-risk, similar diagnostic criteria were applied after excluding influenza and other common respiratory infections\(^{28}\). Iranian guidelines recommend the following case definitions\(^{46}\). A definite case is a child with history, signs and symptoms suggestive of COVID-19, along with abnormal chest CT findings and a positive RT-PCR test. A suspected case is a child with history, signs and symptoms along with abnormal chest CT scan (other causes for abnormal CT scan are ruled out) suggestive of COVID-19, with a negative PCR test. A rejected case is a child with negative RT-PCR test and abnormal chest CT scan due to causes other than COVID-19\(^{46}\).

**Laboratory diagnosis**

Laboratory tests are required for confirming a suspected case as there are no clinical characteristics that are specific to COVID-19. At present, this is based on the molecular detection of SARS-CoV-2 genetic material in clinical specimens and needs to be carried out in a laboratory with at least biosafety level-2 or equivalent facilities\(^{47}\).

**Real-time reverse transcription-polymerase chain reaction (RT-PCR) test**

Nasopharyngeal or throat swabs are the preferred specimens, and viral nucleic acid amplification test (NAAT) employing real-time RT-PCR is performed. Different assays target different areas of the viral genome - open reading frame (orf) 1a and 1b, RNA-dependent RNA polymerase (RdRp), envelope (E), nucleocapsid (N) or spike (S) protein genes\(^{47}\). A sample is considered positive if any of the target genes are amplified from an area with known SARS-CoV-2 circulation, while in geographic regions with no known virus circulation, minimum two different gene targets should be positive or one positive NAAT for Betacoronavirus and whole- or partial-genome sequencing of the virus\(^{47}\). Another nucleic acid assay for the detection of SARS-CoV-2 under development is reverse-transcription loop-mediated isothermal amplification (LAMP)\(^{48}\). This is a rapid and cost-effective assay as it requires only heating and visual inspection. This test is shown to be effective in detecting SARS-CoV-2 viral RNA and may be used as an alternative tool for RT-PCR, however, needs validation for clinical application.

**Serological assays**

Although real-time RT-PCR is the gold standard for SARS-CoV-2 diagnosis at present, usefulness of serological assays needs exploration, especially in resource-limited settings. A preliminary study on 82 confirmed and 58 probable cases of COVID-19 in adults showed appearance of specific IgM antibodies on day five with a positivity rate of 85.4 per cent and IgG antibodies on day 14 with a positivity rate of 77.9 per cent\(^{49}\). IgM and IgG serological tests are available in ELISA and also as a rapid test format. Serological tests are not very useful for diagnosis in early phase of the illness as antibodies take time to develop\(^{50}\). However, serological tests are recommended for epidemiologic research and disease surveillance. These are especially useful in retrospective identification of asymptomatic cases, and to identify and monitor individuals recovered from COVID-19 infection whose antibodies may serve to treat patients through convalescent plasma therapy. Utility of serological assays, alone or in combination with RT-PCR, needs to be explored in children as they may present late to healthcare facilities because of the milder nature of the disease.

**Other laboratory findings**

In COVID-19 patients, abnormalities are noted in routine laboratory tests as well, which may be helpful in clinical assessment and prognostication. In general, leucopenia, lymphopaenia and thrombocytopaenia are noted in both adults and children\(^{51,52}\). Increased blood levels of lactate dehydrogenase, procalcitonin and D-dimer are seen in severe disease\(^{23,51}\). In a study of 36 COVID-19-affected children\(^{23}\), increased creatine kinase MB (31%), lymphocytopenia (31%), leucocytopenia (19%) and increased procalcitonin levels (17%) were the typical findings observed.
Variables significantly associated with severe disease were increased levels of D-dimer, procalcitonin and creatine kinase MB and decreased lymphocytes. D-dimer levels may be useful to estimate the severity of COVID-19. Increased procalcitonin values may lead to about five-fold increased risk of severe disease. Elevated levels of hepatic enzymes such as alanine aminotransferase and aspartate aminotransferase are seen, especially in severe cases of COVID-19 in adults, but not in children.

**Imaging findings**

Imaging tools such as X-ray, CT scan and ultrasonography are valuable for diagnostic support as well as for assessment of progression of disease and follow up.

**Chest X-ray and CT scan**

The most commonly reported X-ray and CT findings of COVID-19 are lung consolidation and ground-glass opacities. COVID-19 and other viral pneumonias generally show pulmonary opacities in more than one lobe, whereas community-acquired bacterial pneumonia is usually unilateral and involves a single lobe. Bilateral multifocal air-space disease with lower lung distribution on X-ray can be an important clue to COVID-19 pneumonia. Peripheral lung involvement is reported as a unique and to some extent a specific feature of COVID-19 pneumonia. Pleural effusions, cavitation in the lungs and pneumothorax are rare.

Chest X-ray is less sensitive in detecting COVID-19 pulmonary disease in comparison to CT scan. However, chest X-ray minimizes the risk of cross-infection, which usually occurs post-CT scan if decontamination is not done properly. X-ray, especially portable, offers several advantages in resource-limited settings. Role of X-ray for diagnosing COVID-19 where RT-PCR facilities are not available needs to be explored.

In a study of 36 children, 19 (53%) cases showed ground-glass opacities in the lung in CT scan, suggesting pneumonia. Mixed ground-glass opacity and consolidation lesions (36%), consolidations (32%) and ground-glass opacities (14%) were the major CT findings observed in 22 paediatric cases. Peripheral distribution (45%) of pulmonary lesions was predominant, and majority of the lesions were multilobar (68%). Another study (20 children) reported elevated procalcitonin levels and consolidation with surrounding halo sign in the chest CT scan as characteristic features in children.

**Ultrasoundogram**

A study on 10 children affected with COVID-19 indicated the application of ultrasonography of lungs in detecting COVID-19 pneumonia. Described findings include vertical artefacts (70%), pleural irregularities (60%), areas of white lung (10%) and sub-pleural consolidations (10%). Bed-side ultrasound offers several practical advantages such as ease of operation and decontamination and lowering the radiation exposure of the patients, and hence, its usefulness needs further exploration.

**Clinical management**

**Supportive treatment**

The mainstay of clinical management is supportive. Children with mild-to-moderate illness may be managed with symptomatic treatment at home, with strict adherence to infection control measures by the family. However, the consideration for home management versus health centre/hospital may vary from region to region, based on the stage of the epidemic and the availability of resources. As per the Indian guidelines, the cases need to be clinically categorized as very mild/mild, moderate or severe and accordingly admitted to (i) COVID care centre, (ii) dedicated COVID health centre, or (iii) dedicated COVID hospital, respectively. However, very mild/pre-symptomatic/asymptomatic children having the requisite facility at his/her residence for self-isolation will have the option for home management. Control of body temperature and maintenance of humidity of airways are recommended as the important considerations in symptomatic management in the updated Chinese guidelines. Care should be taken not to use mask in young children because of the risk of suffocation. Parents should be clearly explained about the danger signs and instructed to take the child to health facility immediately, if any adverse events occur.

Children with moderate-to-severe illness are better managed in a designated COVID-19 health centre or hospital. Respiratory support varying from oxygen therapy to mechanical ventilation might be required. Children on non-invasive ventilation for two hours without improvement, or unable to tolerate non-invasive mechanical ventilation, with excessive airway secretions, severe cough or haemodynamic compromise, need to be put on invasive mechanical ventilation. Low-tidal volume lung protective ventilation strategy is preferred to reduce ventilator-associated lung
injury. Prone position ventilation, lung recruitment or extracorporeal membrane oxygenation (ECMO) may be considered. Some consensus guidelines recommend short-course steroid therapy for moderate and severe cases. Standard protocols need to be followed for the management of sepsis and shock. Hypercoagulable states may necessitate the use of anticoagulants. Bacterial infections need to be taken care of by appropriate use of antibiotics. Management of co-infections with other respiratory viral pathogens such as influenza with oseltamivir is also important. Nutrition and fluid management need to be done carefully.

**Specific treatment**

As of now, there is no specific therapy approved for COVID-19. Clinical trials are in progress in adults, and similar studies need to be carried out in children also. Generally, use of an experimental therapy outside a clinical trial setting is not recommended. Antiviral treatment is likely to be beneficial in the first phase of the illness. Immunomodulatory treatment may only be indicated if there is a clear evidence of hyper-inflammation, or in the second phase of the illness, as there is limited evidence currently. However, compassionate off-label treatment may be given on a case-to-case basis. There are anecdotal reports of off-label treatment with various agents such as antivirals, immunomodulatory agents, immunoglobulins and even convalescent plasma therapy (Table II).

In one case series, 36 children were given interferon α by aerosolization twice a day and 14 of them additionally received lopinavir-ritonavir syrup. Since it was an observational study without any control arm and all the children were of mild-to-moderate severity illness, it was not possible to infer the effect of the antiviral medication. In a recent study on children admitted in the ICU with COVID-19, various antivirals and immunomodulatory drugs such as chloroquine, azithromycin, remdisivir, tocilizumab and convalescent plasma therapy have been tried.

**Consensus treatment guidelines**

There are consensus treatment guidelines and position statements published by the various government bodies as well as professional societies of some countries. A summary of the salient features of different consensus treatment guidelines for children with COVID-19 published from China, Iran, the UK and India is provided in Table III.

Differences in recommendations by various bodies are noted as the guidelines need to suit the country situation and are based primarily on anecdotal reports and preliminary experiences with COVID-19 in addition to lessons learnt from SARS and MERS epidemics. It is also to be pointed out that some guidelines are developed during the early phase of the pandemic, based on knowledge and experience at that point of time. Hence, recommendations in some of the guidelines may not hold merit in the current situation and require updating. Despite limitations, these guidelines are useful in triaging and optimizing utilization of resources and provision of standard and scientific treatment. Treating physicians may evaluate the situation on a case-to-case basis and take appropriate decisions.

**COVID-19 in pregnant women and neonates: Specific concerns**

Although pregnant women were found to be infected with COVID-19, no increased risk of severity was seen unlike that observed during the H1N1 influenza pandemic. In the largest series of 147 infected pregnant women from China, eight per cent developed severe and one per cent developed critical illness; however, the details are not available. In another series of 116 cases, 6.9 per cent had severe illness; fever (50.9%) and cough (28.4%) were the most common symptoms. Interestingly, 23.3 per cent patients presented without symptoms; 86 per cent of women underwent caesarean delivery. Among the 100 neonates tested, 86 were found to be negative for SARS-CoV-2. The data suggested that infection with SARS-CoV-2 during pregnancy was not associated with higher risk of spontaneous abortion/preterm birth. Clinical features, severity, pregnancy outcome, treatment and neonatal infection in different published case series are summarized in Table IV. Separate delivery rooms as well as surgical theatres are necessary for COVID-19-suspected or -confirmed mothers. Neonatal resuscitation corners need to be located at least two meters away from the delivery table. Unless for obstetric indications, vaginal delivery is preferred.

Neonates may acquire infection from the infected mother or from the infected healthcare worker. Reported clinical manifestations include fever, lethargy and respiratory distress. In general, new-born develops mild illness and has good prognosis. Currently, there is a lack of evidence to suggest intrauterine or
| Country | Consensus guidelines/position statement - salient features |
|---------|---------------------------------------------------------|
| China   | **Supportive treatment**  
Control of body temperature with antipyretics and expectorant drugs to avoid respiratory tract obstruction.  
For hypoxia, effective oxygen therapy with nasal catheter, mask oxygen. Nasal high-flow oxygen therapy, and non-invasive or invasive mechanical ventilation as appropriate.  
Prone position and lung protective ventilation strategy is preferred. ECMO may be tried in refractory cases.  
Glucocorticoids in severe cases 3-5 days for ARDS.  
Increased D-dimer and at high-risk of thrombosis - low molecular weight heparin and anticoagulants may be initiated.  
Oseltamivir and other anti-influenza agents for co-infection with influenza and others. |

**Specific treatment**  
IFN-alpha spray/nebulization; plasma exchange, immunoglobulin or convalescent plasma on case-to-case basis. Traditional Chinese medicine may also be given.  
Updated guidelines do not recommend lopinavir/ritonavir, ribavirin or chloroquine phosphate in paediatric patients. |
| Iran    | **Supportive treatment**  
Supportive therapy with antipyretics, fluids and electrolytes replacement, analgesia and ventilation as per requirement. |

**Specific treatment**  
ICU-admitted patients: Treatment for patients who were admitted in ICU included combined antiviral agents and immunomodulators [oseltamivir + hydroxychloroquine + kaletra (lopinavir + ritonavir)] ribavirin and if necessary, antibiotics according to the patient’s situation.  
Moderate to severe pneumonia: Treatment for these patients included combined antiviral agents and immunomodulators [oseltamivir + hydroxychloroquine + kaletra (lopinavir + ritonavir)], and if necessary antibiotics according to the patient’s situation.  
Mild pneumonia with risk factor: Treatment for these patients included combined antiviral agents and immunomodulators (oseltamivir + hydroxychloroquine), and if necessary antibiotics according to the patient’s situation.  
Mild pneumonia without risk factor: These patients should be placed in a watchful waiting programme and followed. Treatment in these groups is optional and related to physician’s decision according to the situation. It may include oseltamivir-hydroxychloroquine, and if necessary, antibiotics. |
| UK and Ireland | Mild to moderate disease: Supportive care only.  
Severe disease (mild - moderate ARDS): Supportive care, treatment with antivirals may be considered. Treatment with immunomodulatory therapy if evidence of hyperinflammation (raised CRP, ferritin, IL6, sCD25).  
Critical disease (severe ARDS or septic shock or altered consciousness or multi-organ failure): Supportive care treatment with antivirals. Treatment with immunomodulatory therapy may be considered if evidence of hyperinflammation (raised CRP, ferritin, IL6, sCD25).  
Antiviral therapy: Lopinavir, ritonavir + ribavirin or chloroquine or remdesivir.  
Immune modulation therapy: Tocilizumab and anakinra. |

*Contd...*
| Country | Consensus guidelines/position statement - salient features |
|---------|----------------------------------------------------------|
| India   | **Supportive treatment**                                  |
|         | Mild cases: Antipyretics/analgesics/antitussives/appropriate hydration and adequate nutrition.  
|         | Moderate cases: Antipyretics/analgesics/antitussives/appropriate hydration and adequate nutrition.  
|         | Oxygen support (target SpO\(_2\) 92-96%), prophylactic anticoagulation, corticosteroids (methyl prednisolone/dexamethasone), Close monitoring for worsening.  
|         | Severe cases: Supportive therapy to continue as in moderate cases. On failure of standard oxygen therapy, consider HFNO/non-invasive mechanical ventilation or mechanical ventilation.  
|         | Lung protective ventilation - prone position, low tidal volume, lower inspiratory pressures, higher PEEP.  
|         | Management of septic shock, bacterial infection  
|         | Anticoagulation  
|         | **Specific treatment (investigational therapy/repurposed or off-label therapy)**  
|         | Mild cases with risk factors and in moderate cases - Consider hydroxychloroquine (dose 400 mg BD - for 1 day followed by 200 mg BD for 4 days) in patients above 12 yr. These drugs should be administered under close medical supervision, with monitoring for side effects including QTc interval.  
|         | In severe cases hydroxychloroquine is to be avoided.  
|         | In selected moderate cases with worsening and severe cases, remdesivir (children above 12 yr), convalescent plasma or tocilizumab may be considered. |

ARDS, acute respiratory distress syndrome; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; CRP, C-reactive protein; SpO\(_2\), oxygen saturation; HFNO, high-flow nasal cannula oxygenation; PEEP, positive end-expiratory pressure

Transplacental transmission of SARS-CoV-2\(^{13,63,67}\). Possibilities of intrauterine vertical transmission was investigated in a small group of pregnant women (n=6) in samples such as amniotic fluid, cord blood, breast milk and neonatal throat swab. All the samples were found to be negative for SARS-CoV-2, suggesting that vertical transmission was unlikely\(^{63}\). However, reports of increased IgM levels detected in the blood sample of three neonates born to mothers affected by COVID-19 are of concern; the RT-PCR tests carried out from the samples from these neonates were negative and the issue of vertical infection remained unresolved\(^{14,68}\). Future studies in pregnant women should carefully address such paradoxes.

The Italian Society of Neonatology suggests that under strict practices of infection control, breastfeeding is advisable by COVID-19-positive mothers. However, neonates need to be managed separately if mothers are too sick to care for them\(^{69}\). The Federation of Obstetric and Gynecological Societies of India, National Neonatology Forum of India, and Indian Academy of Pediatrics have issued guidelines for perinatal-neonatal management of COVID-19, which suggest direct breastfeeding\(^{61}\). Mother should wear mask and wash hands frequently including before breastfeeding. If breastfeeding is not feasible due to maternal or neonatal condition, expressed breast milk may be considered. Recently, RNA of SARS-CoV-2 has been detected in breast milk from an infected mother\(^{70}\). Hence, there is a need to exercise caution and wait for further research.

### Prognosis and long-term effects

Individuals who recover from the illness generally do well. However, this is a new disease, and hence, the long-term effects of COVID-19 in the affected individuals are unknown. A few observations during the previous SARS epidemic are noteworthy in this context. A study reported mild reduction in exercise tolerance and muscle weakness for a variable period of 3-6 months in children recovered from SARS\(^{71}\). Further, diffuse thinning as well as shedding of hairs was noted in some children. However, lung functions and psychological status were normal\(^{71}\). In affected adults, pulmonary fibrosis was reported in some individuals after recovery\(^{72}\). In a study on 25 individuals recovered from SARS infection, metabolic disruptions such as increase in phosphatidylinositol and lysophosphatidylinositol levels were observed 12 years later. It was not clear whether this was the effect of the viral infection or due to high-dose methyl prednisolone received for treatment\(^{73}\). Although there is a lack of evidence of vertical transmission in the current scenario, but evaluation of children born to women who were COVID-19 affected during early phase of pregnancy may be advisable to know the teratogenic effect, if any.
### Table IV. Clinical profile of coronavirus disease 2019 in pregnant women and neonates

| Study                  | Country                      | Number of pregnant women | Clinical features, n (%) | Delivery and pregnancy outcome, n (%) | Treatment, n (%)                                                                 | Neonatal infection/outcome                                      |
|------------------------|------------------------------|--------------------------|--------------------------|--------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------|
| WHO-China-Joint-Mission³ | China (as of February 20, 2020) | 147 (64 confirmed)       | Severe disease (8)       | N/A                                  | N/A                                                                             | N/A                                                           |
| Yan et al³             | China (January 20 to March 24, 2020) | 116 (retrospective case series) (65 confirmed) | Characteristics of 116 cases: Fever 59 (50.9) Cough 33 (28.4) Fatigue 15 (12.9) Shortness of breath 9 (7.8) Sore throat 10 (8.6) Myalgia 6 (5.2) Dyspnoea 3 (2.6) Diarrhoea 1 (0.9) No symptoms 27 (23.3) Severe cases 8 (6.9) | Caesarean delivery - 85 (85.9) Vaginal delivery - 14 (14.1) One of eight patients (12.5) who presented in the first- and early-second-trimester had a missed spontaneous abortion The rate of spontaneous preterm birth before 37 wk was 6.1% (6/99) Twenty one of 99 patients (21.2) who had delivered, had preterm birth, including six with preterm premature rupture of membranes One neonatal death due to asphyxia | Following treatment was given to 8 severe cases Antibiotic therapy 109 (94.0) Antiviral therapy 63 (54.3) Use of corticosteroid 37 (31.9) ICU admission 8 (6.9) Non-invasive ventilation 6 (5.2) Invasive mechanical ventilation 2 (1.7) ECMO 1 (0.9) Plasmapheresis 1 (0.9) Arbidol/oseltamivir/ aciclovir/ribavirin/interferon alone or in combination | 14 neonates tested positive out of 100 Ten neonates had paired amniotic fluid and cord blood samples that were tested negative for SARS-CoV-2 |
| Zeng et al²            | China (January to February 2020) Wuhan Children’s Hospital | 33 (cohort study)         | Fever on admission 8 (24) Cough 30 (33) Postpartum fever 5 (15) Pneumonia 33 (100) Premature rupture of membranes 3 (9) | 26 (79) delivered by caesarean section | N/A                                                                            | All three (3/33) infected neonates recovered One had respiratory distress |

Contd...
| Study        | Country                                      | Number of pregnant women | Clinical features, n (%)                                      | Delivery and pregnancy outcome, n (%)                                                                 | Treatment, n (%)                                                                 | Neonatal infection/ outcome |
|-------------|----------------------------------------------|--------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------|
| Chen *et al* | China (January 20-31, 2020) Zhongnan Hospital, Wuhan | 9 (retrospective case series) | Fever on admission 7 (78) Post-partum fever 6 (67) Myalgie 3 (33) Malaise 2 (22) Cough 4 (44) Dyspnoea 1 (11) Sore throat 2 (22) Diarrhoea 1 (11) Foetal distress noted in two cases | All were in third trimester and delivered by caesarean section | Oxygen support (nasal cannula) 9 (100) Antiviral therapy 6 (67) Antibiotic therapy 9 (100) | Nine neonates SARS-CoV-2 negative SARS-CoV-2 negative in amniotic fluid, cord blood, neonatal throat swab, and breast milk in 6 patients |
| Zhu *et al* | China (January 20 to February 5, 2020) Five hospitals in Hubei | 9 (retrospective case series) | Fever 9 (100) Cough 4 (44) Intrauterine foetal distress 6 (67) Premature rupture of membranes 3 (33) | Caesarean delivery - 7 (77.8) Vaginal delivery - 2 (22.2) | Postpartum antiretroviral therapy (oral oseltamivir) is given for 4 mothers | RT-PCR for all neonates was negative. However, intrauterine foetal distress present in 6 cases One neonate died |
| Wu *et al*  | China (January 23 to February 10, 2020) Maternal and Child Health Hospital of Hubei Province, Wuhan | 8 (retrospective case series) | Post-partum fever 2 (33) All women asymptomatic before delivery but became symptomatic post-partum | All were in third trimester Caesarean delivery - 6 (75) Vaginal delivery - 2 (25) | All patients received empirical antibiotic treatment and supportive care | N/A |
| Yu *et al*  | China (January 1 to February 8, 2020) Tongji Hospital, Wuhan | 7 (retrospective case series) | Fever 6 (86) Cough 1 (14) Shortness of breath 1 (14) Diarrhoea 1 (14) Pneumonia 6 (86) H1N1 infection 2 (28) | Caesarean delivery - 7 (100) | All patients received oxygen therapy Antiviral treatment (oseltamivir and ganciclovir) Antibiotic treatment (cephalosporins, quinolones, and macrolides), interferon and arbidol tablets Traditional Chinese medicines (granules and Lianhuqingwen capsules) were also given Methylprednisolone was given to 5 patients (71) after caesarean section | One infant was positive 36 h after birth |

Contd...
Quarantine, hospital admission and stigma associated with the disease have negative psychosocial effect on the affected individual. At the same time, school closure, lack of play activities and home confinement during the lockdown period seem to have negatively affected the uninfected children. A study from China reported 22.6 per cent of students having depressive symptoms and 18.9 per cent symptoms of anxiety during the lockdown period\(^4\). Apart from the direct effects on the health due to the virus infection, there are many other ways through which children are affected. The most notable are the immediate socio-economic impact of the measures taken to mitigate the pandemic and the long-term effects of delay in the implementation of the sustainable development goals\(^7\).

**Prevention of COVID-19: Distinct facets in children, caregivers and community**

Until an effective vaccine is available, containment and mitigation strategies largely depend on non-pharmacological public health measures which include physical distancing, personal hygiene, frequent hand washing with sanitizers or soap and water, mass masking, cleaning of floors and surfaces and drastic measures such as countrywide lockdown. Isolation of the infected, tracing the contacts, quarantine of the exposed individuals and protection of the vulnerable groups from exposure are crucial.

Special precautions should be taken for the high-risk groups, such as young infants, those suffering from comorbid conditions and those on immunosuppressive therapy. Specific measures need to be taken to limit exposure in the schools and day-care centres, once these reopen. All routine vaccinations in the universal immunization programme should be given without delay\(^7\). Quarantining exposed children is a difficult task; home quarantine with a caregiver in a separate room may be suitable. Mother-to-child transmission is a special scenario; the need of strict adherence to infection prevention and control measures during delivery is important as described earlier.

Second aspect is the protection of the elderly and vulnerable from an infected child at home. It is speculated that aerosols may be generated while crying and screaming in young children\(^7\). In addition to prolonged viral shedding by respiratory route, virus shedding is also reported in the faeces of children\(^1,12\). Therefore, caregivers and healthcare workers are encouraged to wear personal protective equipment at homes or hospitals while handling the infected children.
Third aspect of concern is the risk to community from children with asymptomatic or mild infection, especially during re-opening of schools and day-care centres. Asymptomatic carriers with prolonged viral shedding in the respiratory and faecal samples pose risk to the contacts. Several case series have reported relatively high proportion of asymptomatic cases varying from 13 to 16 per cent (Table II). However, during COVID-19 contact tracing, the China/WHO Joint Commission did not find any transmission event occurring from a child to an adult. In this scenario, studies are warranted to assess the extent of asymptomatic infection in children and their role as links in transmission chain in the community. Sero-surveys would be useful for this purpose. It is also important to mention that strict implementation of non-pharmacological measures may be difficult in young children.

Why COVID-19-affected children manifest only mild illness?

Variable severity of viral infection in different age groups is not a new phenomenon. With their immature immune system, in general, children are severely affected by respiratory viruses such as the influenza and respiratory syncytial virus in comparison to adults. However, on the contrary, relative sparing of children and the mild nature of COVID-19 in them have perplexed the epidemiologists, clinicians and scientists alike. Currently, there are no clear answers to this; there are only theories and hypotheses that are summarized below:

**Angiotensin-converting enzyme 2 (ACE2) and renin angiotensin system (RAS)**

A biologically plausible explanation is that the cellular expression of entry receptor ACE2 and the binding between the receptor and the spike protein of the virus may be different in children from that in adults. Studies are needed to find the difference in renin angiotensin system (RAS) pathophysiology in children and adults and its possible role in determining the differential outcomes of COVID-19. Dysregulation of RAS is known in comorbid conditions such as hypertension, cardiac diseases and diabetes. Abnormalities in RAS were noted in SARS and MERS virus infection also.

**Differences in immune system of adults versus children**

The difference in immune systems of children and adults also needs special attention while considering this issue. Immune system in children is not fully developed. There is a possibility that children are not mounting an intense inflammatory response, and hence, the host-mediated damage is limited. On the other hand, adults may be at risk of severe disease due to their different immune response characterized by excessive inflammation.

**Role of childhood vaccinations**

Children receive several doses of different vaccines as part of the universal immunization programme, and whether the resulting immune stimulation has any role in protection from COVID-19 needs to be elucidated. Cross-protection by antibodies generated following measles vaccination and cell-mediated immune response generated by BCG vaccination also need evaluation.

**Role of other human coronaviruses and other infections in children**

Children frequently suffer from mild infections by the respiratory and GI viruses. It needs to be seen whether pre-existing antibodies against human coronavirus infections causing common cold or other respiratory virus infections or GI infections confer cross-protection against COVID-19.

**Role of co-infections**

During H1N1 pandemic, bacterial co-infection with *Streptococcus pneumoniae* was common which caused considerable morbidity. Data on co-infections with bacterial pathogens are not yet available for COVID-19 patients. One group of researchers put forward a hypothesis that co-infection with pathogens such as *Bordetella* due to waning of vaccine-mediated immunity in adults could be a possible reason for the severity in COVID-19.

**Knowledge gaps and research priorities**

Despite the global spread, epidemiology and clinical patterns of COVID-19 in children remain largely unclear, and emerging data indicate significant differences from adults. There is a need for systematic research to address the knowledge gaps. Future COVID-19 studies in children should focus on the extra-pulmonary and atypical clinical features, risk factors for severe illness, markers of severity, role of imaging, optimal supportive care and trials with newer therapies - antivirals and immunomodulatory drugs. Another area that needs attention is developing case definitions and testing strategies specific to children, as the initial strategy may not be suitable when community
transmission occurs. From an epidemiological point of view, high proportion of asymptomatic infection in children and their role in disease transmission needs to be elucidated. Drug prophylaxis in exposed children and child-centric issues in quarantining need to be addressed. The psychosocial effects of closure of schools, lack of play activities and home confinement during lockdown need attention of researchers.

Conclusion
COVID-19 in children poses challenges different from adults. Although the numbers of infected children and the severity of illness are expected to be low, healthcare professionals need to be prepared to face the situation. At present, it is uncertain how long the pandemic may continue and what would be the long-term effects. However, far-reaching socio-economic, political and environmental effects are likely, and the post-COVID-19 pandemic world is not going to be the same. The impacts of COVID-19 in children may go far beyond health including psychosocial, economical and educational and others that are beyond the scope of this article. It would be interesting to observe how children, whether infected or uninfected, grow up in the post-COVID-19 pandemic world.

Acknowledgment: Authors thank Dr Ashwani Kumar, Director, ICMR-Vector Control Research Centre, for reviewing this manuscript.

Financial support & sponsorship: None.

Conflicts of Interest: None.

References
1. World Health Organization. Coronavirus disease (COVID-19): Situation Report - 169. Geneva: WHO; 2020.
2. Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B, et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res 2020; 151: 490-2.
3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Wkly 2020; 2: 113-22.
4. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020; 323: 1335.
5. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343-6.
6. Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020; 35: e112.
7. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J 2020; 39: 355-68.
8. Tan WJ, Zhao X, Ma XJ, Wang W, Niu P, Xu W, et al. A novel coronavirus genome identified in a cluster of pneumonia cases - Wuhan, China 2019-2020. China CDC Wkly 2020; 2: 61-2.
9. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf; accessed on March 31, 2020.
10. Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, et al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). China CDC Wkly 2020; 2: 123-4.
11. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 2020; 26: 502-5.
12. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case series of children with 2019 novel coronavirus infection: Clinical and epidemiological features. Clin Infect Dis 2020; ciaa198.
13. Yan J, Guo J, Fan C, Yuan J, Xu Y, Li J, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases. Am J Obstet Gynecol 2020; 223: 111.e1-14.
14. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA 2020; 323: 1848-9.
15. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020; 172: 577-82.
16. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020; 581: 465-9.
17. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20: 656-7.
18. Cao W, Li T. COVID-19: Towards understanding of pathogenesis. Cell Res 2020; 30: 367-9.
19. Yuki K, Fujioji M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020. pii: 108427.
20. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80.
21. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. *Lancet* 2020; 395 : 1417-8.

22. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; 8 : 420-2.

23. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: An observational cohort study. *Lancet Infect Dis* 2020; 20 : 689-96.

24. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol* 2020; 55 : 1169-74.

25. Bi Q, Wu Y, Mei S,Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. *Lancet Infect Dis* 2020. doi: 10.1016/S1473-3099(20)30287-5.

26. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* 2020; 368 : 1481-6.

27. Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, et al. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. *Montaldi Arch Chest Dis* 2020; 10 : 90.

28. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. *Pediatrics* 2020; 145 : e20200702.

29. CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States. *MMWR Morb Mortal Wkly Rep* 2020; 69 : 422-6.

30. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. *N Engl J Med* 2020; 382 : 1663-5.

31. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. *JAMA Pediatr* 2020. doi: 10.1001/jamapediatrics.2020.1948.

32. Tagarro A, Epaleta C, Santos M, Sanz-Santacuefemia FJ, Otheo A, Moraleda C, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr* 2020. pii: e201346.

33. Wang D, Ju XL, Xie F, Lu Y, Li FY, Huang HH, et al. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China. *Zhonghua Er Ke Za Zhi* 2020; 58 : 269-74.

34. Zheng F, Liao C, Fan QH, Chen HB, Zhao XG, Xie ZG, et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. *Curr Med Sci* 2020; 40 : 275-80.

35. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: A single center’s observational study. *World J Pediatr* 2020; 16 : 251-9.

36. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020; 109 : 1088-95.

37. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. *JAMA Pediatr* 2020. doi: 10.1001/jamapediatrics.2020.1467.

38. Shen KL, Yang YH, Jiang RM, Wang TY, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: Experts’ consensus statement (condensed version of the second edition). *World J Pediatr* 2020; 1-8.

39. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-like lesions during COVID-19 epidemic: A preliminary study on 63 patients. *J Eur Acad Dermatol Venereol* 2020; 34 : e291-3.

40. Landa N, Mendieta-Eckert M, Fonda-Pascual A, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19. *Int J Dermatol* 2020; 59 : 739-43.

41. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. *Lancet* 2020; 395 : 1481.

42. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, et al. COVID-19 and Kawasaki disease: Novel virus and novel case. *Hosp Pediatr* 2020; 10 : 537-40.

43. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Available from: https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19, accessed on May 17, 2020.

44. World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: Interim guidance, 20 March 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/331506/WHO-2019-nCoV-SurveillanceGuidance-2020.6-eng.pdf?sequence =1&isAllowed=y, accessed on May 15, 2020.

45. Directorate General of Health Services (EMR Division), Ministry of Health and Family Welfare, Government of India. Clinical management protocol: COVID-19. Version 5. New Delhi: MoHFW, Government of India; 2020.

46. Karimi A, Rafiei Tabatabaei S, Rajabnejad M, Pourmoghaddas Z, Rahimi H. An algorithmic approach to diagnosis and treatment of coronavirus disease 2019 (COVID-19) in children: Iranian Expert’s Consensus Statement. *Arch Pediatr Infect Dis* 2020; 8 : E102400.

47. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim guidance, 2 March, 2020. Available from: https://apps.who.int/iris/handle/10665/331329, accessed on May 12, 2020.
48. Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. *ACS Cent Sci* 2020; 6: 591-605.

49. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). *Clin Infect Dis* 2020; ciaa310.

50. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *JAMA* 2020. doi: 10.1001/ jama.2020.8259.

51. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. *Clin Chem Lab Med* 2020; 58 : 1131-4.

52. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. *Clin Chem Lab Med* 2020; 58 : 1135-8.

53. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. *J Thromb Haemost* 2020; 18 : 1324-9.

54. Jacobi A, Chung M, Bernheim A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review. *Clin Imaging* 2020; 64 : 35-42.

55. Li B, Shen J, Li L, Yu C. Radiographic and clinical features of children with coronavirus disease (COVID-19) pneumonia. *Indian Pediatr* 2020; 57 : 423-6.

56. Musolino AM, Supino MC, Buonsenso D, Ferro V, Valentini P, Magistrelli A, et al. Lung ultrasound in children with COVID-19: Preliminary findings. *Ultrasound Med Biol* 2020; 46 : 2094-8.

57. Denina M, Scalfaro C, Silvestro E, Pruccioli G, Mignone F, Zoppo M, et al. Lung ultrasound in children with COVID-19. *Pediatrics* 2020; 146 : e20201157.

58. Ministry of Health & Family Welfare, Government of India. Revised guidelines for home isolation of very mild/pre-symptomatic/asymptomatic COVID-19 cases. New Delhi: MoHFW, Government of India; 2020.

59. Directorate General of Health Services (EMR Division), Ministry of Health & Family Welfare, Government of India. *Guidance document on appropriate management of suspect/confirmed cases of COVID-19: Types of COVID-19 dedicated facilities*. New Delhi: MoHFW, Government of India; 2020.

60. British Paediatric Allergy, Immunity and Infection Group. BPAIIG Position Statement: SARS-CoV-2 Treatment Guidance. Version 1.2. Available from: https://www.bpaiig.org-news-bpaiig-position-statement-sars-cov-2-treatment-guidance-version-12, accessed on May 13, 2020.

61. Chawla D, Chirala D, Dalwai S, Deorari AK, Ganatra A, Gandhi A, et al. Perinatal-neonatal management of COVID-19 infection – Guidelines of the Federation of Obstetric and Gynecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP). *Indian Pediatr* 2020; 57 : 536-48.

62. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr* 2020; 174 : 722-5.

63. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* 2020; 395 : 809-15.

64. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr* 2020; 9 : 51-60.

65. Wu C, Yang W, Wu X, Zhang T, Zhao Y, Ren W, et al. Clinical manifestation and laboratory characteristics of SARS-CoV-2 infection in pregnant women. *Viril Sin* 2020; 35 : 305-10.

66. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020; 20 : 559-64.

67. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy outcomes. *Arch Pathol Lab Med* 2020. doi: 10.5858/arpa.2020-0901-SA.

68. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA* 2020; 323 : 1846-8.

69. Davanzo R, Moro G, Sandri F, Agosti M, Moretti C, Mosca F. Breastfeeding and coronavirus disease-2019: Ad interim indications of the Italian Society of Neonatology endorsed by the Union of European Neonatal & Perinatal Societies. *Matern Child Nutr* 2020; 16 : e13010.

70. Groß R, Conzelmann C, Müller JA, Stenger S, Steinhart K, Kirchhoff F, et al. Detection of SARS-CoV-2 in human breastmilk. *Lancet* 2020; 395 : 1757-8.

71. Leung CW, Kwan YW, Ko PW, Chiu SS, Loung PY, Fong NC, et al. Severe acute respiratory syndrome among children. *Pediatrics* 2004; 113 : e535-43.

72. Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience. *Radiology* 2003; 228 : 810-5.

73. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. *Sci Rep* 2017; 7 : 9110.

74. Xie X, Xue Q, Zhou Y, Zhu K, Liu Q, Zhang J, et al. Mental health status among children in home confinement during the coronavirus disease 2019 outbreak in Hubei Province, China. *JAMA Pediatr* 2020; e201619.

75. United Nations. Policy brief: The impact of COVID-19 on children.. Available from: https://unsdg.un.org/sites/ default/files/2020-04/160420_Covid_Children_Policy_Brief.pdf, accessed on May 14, 2020.
76. Centers for Disease Control and Prevention. *Routine vaccination during the COVID-19 outbreak*. Available from: https://www.cdc.gov/vaccines/parents/visit/vaccination-during-COVID-19.html, accessed on July 10, 2020.

77. Sivabalan S, Srinath MV. Does a crying child enhance the risk for COVID-19 transmission? *Indian Pediatr*. 2020; 57: 586-7.

78. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. *Eur J Pediatr* 2014; 173: 265-76.

79. Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. *Clin Microbiol Rev* 2017; 30: 277-319.

80. Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. *Med Clin North Am* 2017; 101: 129-37.

81. Wevers BA, van der Hoek L. Renin-angiotensin system in human coronavirus pathogenesis. *Future Virol* 2010; 5: 145-61.

82. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* 2015; 282: 20143085.

83. Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. *Mediators Inflamm* 2015; 2015: 692546.

84. Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Coronavirus disease 2019 (COVID-19) in children - What we know so far and what we do not. *Indian Pediatr* 2020; 57: 435-42.

85. Okyay RA, Sahin AR, Aguinada RA, Tasdogan AM. Why are children less affected by COVID-19? Could there be an overlooked bacterial co-Infection? *EJMO* 2020; 4: 104-5.

86. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. *BMC Infect Dis* 2018; 18: 637.

*For correspondence:* Dr Vijesh Sreedhar Kuttiatt, ICMR-Vector Control Research Centre, Indira Nagar, Puducherry 605 006, India

e-mail: vijeshvcrc.icmr@gmail.com